Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Free Cash Flow (2016 - 2025)

Ocular Therapeutix has reported Free Cash Flow over the past 13 years, most recently at -$64.5 million for Q4 2025.

  • Quarterly results put Free Cash Flow at -$64.5 million for Q4 2025, down 62.8% from a year ago — trailing twelve months through Dec 2025 was -$216.9 million (down 59.52% YoY), and the annual figure for FY2025 was -$216.9 million, down 59.52%.
  • Free Cash Flow for Q4 2025 was -$64.5 million at Ocular Therapeutix, down from -$52.3 million in the prior quarter.
  • Over the last five years, Free Cash Flow for OCUL hit a ceiling of -$8.0 million in Q3 2023 and a floor of -$64.5 million in Q4 2025.
  • Median Free Cash Flow over the past 5 years was -$22.5 million (2023), compared with a mean of -$28.0 million.
  • Biggest five-year swings in Free Cash Flow: soared 46.66% in 2022 and later crashed 358.62% in 2024.
  • Ocular Therapeutix's Free Cash Flow stood at -$15.8 million in 2021, then fell by 21.06% to -$19.1 million in 2022, then fell by 19.91% to -$22.9 million in 2023, then tumbled by 72.96% to -$39.6 million in 2024, then tumbled by 62.8% to -$64.5 million in 2025.
  • The last three reported values for Free Cash Flow were -$64.5 million (Q4 2025), -$52.3 million (Q3 2025), and -$53.4 million (Q2 2025) per Business Quant data.